SEATTLE, WA, Pluristyx, a leading provider of induced pluripotent stem cell technologies and proprietary gene editing solutions, announced the successful close of its most recent round of funding.
Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
